Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 0.58 |
| ▸ | CDC7 | O00311 | 15/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 15/20 | 0.58 |
| ▸ | DBF4 | Q9UBU7 | 15/20 | 0.58 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.47 |
| ▸ | CDK9 | P50750 | 3/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1558081 | 0.82 | CDK2 (0.60) | CDK2CDC7CCNE1DBF4CCNT1 | |
| SCHEMBL5112553 | 0.80 | IKBKB (0.47) | CDK2CDK9CDK5 | |
| SCHEMBL12321651 | 0.78 | PDPK1 (0.49) | CDK2CDC7CCNE1DBF4CCNT1 | |
| SCHEMBL12409357 | 0.77 | CDC7 (0.67) | CDK2CDC7CCNE1DBF4CCNT1 | |
| SCHEMBL12280938 | 0.76 | CDK2 (0.49) | CDK2CDC7CCNE1DBF4CCNT1 | |
| SCHEMBL12322306 | 0.75 | CDK2 (0.52) | CDK2CDC7CCNE1DBF4CCNT1 | |
| SCHEMBL12321253 | 0.75 | PDPK1 (0.48) | CDK2CDC7CCNE1DBF4CCNT1 | |
| SCHEMBL28447487 | 0.75 | MPO (0.47) | CDK2CDC7CCNE1DBF4 | |
| SCHEMBL28326793 | 0.75 | CDC7 (0.57) | CDK2CDC7CCNE1DBF4CCNT1 | |
| SCHEMBL2179323 | 0.74 | CDC7 (0.69) | CDK2CDC7CCNE1DBF4CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552019-B2 | Inhibitors of phosphoinositide dependent kinase 1 (PDK1) | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20110230500-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| WO-2010065384-A1 | INHIBITORS OF PHOSPHOINOSITIDE DEPENDENT KINASE 1 (PDK1) | MERCK SHARP & DOHME CORP. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230500-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PDK1, PDPK1, PDK3 | CDK2 48/4885CDC7 129/4885CCNE1 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.